Comparing Approved Checkpoint Inhibitor Regimens and Optimal Treatment Duration

The panel examines practical considerations surrounding the three currently approved frontline checkpoint inhibitor regimens in endometrial cancer, including differences in treatment duration—2 years for pembrolizumab, 3 years for dostarlimab, and until progression for durvalumab with olaparib. Dr. Thaker notes that many patients tolerate maintenance immunotherapy well and may even welcome the continued treatment as a source of reassurance, while the four-year RUBY overall survival data now provide a more informed basis for counseling. Dr. Konecny raises the question of how extended treatment intervals affect monitoring practices, and Dr. Thaker describes her approach of integrating nurse-led check-ins between visits. Dr. Redfern emphasizes the importance of shared decision-making around duration. Dr. Wenham contextualizes the discussion by noting that, absent head-to-head comparisons, the overall survival benefit demonstrated in the RUBY trial remains a meaningful differentiator.